* Arrowhead Pharmaceuticals Inc reported a quarterly adjusted loss of $1.37 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $-1.02. The mean expectation of fifteen analysts for the quarter was for a loss of $1.05 per share. Wall Street expected results to range from $-1.57 to -1 cents per share.
* Reported revenue was zero; analysts expected $63.82 million.
* Arrowhead Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.37.
* The company reported a quarterly loss of $170.54 million.
* Arrowhead Pharmaceuticals Inc shares had fallen by 3.0% this quarter and lost 38.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 1.3% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $50.50 This summary was machine generated from LSEG data November 26 at 10:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.05 -1.37 Missed
Jun. 30 2024 -0.55 -1.38 Missed
Mar. 31 2024 -0.16 -1.02 Missed
Dec. 31 2023 -0.82 -1.24 Missed
Comments